Cargando…

Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series

We present a case series of three patients with COVID-19 who were admitted to our intensive care unit due to acute respiratory distress syndrome, brain infarction, pulmonary embolism, and antiphospholipid antibodies. We applied therapeutic plasma exchange on all cases. On intensive care unit admissi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharthy, Abdulrahman, Faqihi, Fahad, Balhamar, Abdullah, Memish, Ziad A, Karakitsos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550946/
https://www.ncbi.nlm.nih.gov/pubmed/33101686
http://dx.doi.org/10.1177/2050313X20964089
_version_ 1783593073820827648
author Alharthy, Abdulrahman
Faqihi, Fahad
Balhamar, Abdullah
Memish, Ziad A
Karakitsos, Dimitrios
author_facet Alharthy, Abdulrahman
Faqihi, Fahad
Balhamar, Abdullah
Memish, Ziad A
Karakitsos, Dimitrios
author_sort Alharthy, Abdulrahman
collection PubMed
description We present a case series of three patients with COVID-19 who were admitted to our intensive care unit due to acute respiratory distress syndrome, brain infarction, pulmonary embolism, and antiphospholipid antibodies. We applied therapeutic plasma exchange on all cases. On intensive care unit admission, all patients had low (<10) Glasgow Coma Scale, and central nervous imaging showed multiple brain infarctions. COVID-19 was confirmed by reverse transcriptase polymerase chain reaction assays. Patients underwent rescue therapeutic plasma exchange using the Spectra Optia(TM) Apheresis System (Terumo BCT Inc., USA), which operates with acid-citrate dextrose anticoagulant as per Kidney Disease Improving Global Outcomes 2019 guidelines. A dose of 1.5 plasma volume was used for the first dose and then 1 plasma volume daily for a total of five doses. Plasma was replaced with Octaplas LG(®) (Octapharma AG, USA), which is an artificial fresh frozen plasma product that has undergone viral inactivation by prion reduction technology. We administered ARDS-net/prone positioning ventilation, empiric antiviral treatment, therapeutic anticoagulation, and intensive care unit supportive care. Laboratory tests showed lymphocytopenia; elevated levels of D-dimer, fibrinogen, total bilirubin, C-reactive protein, lactate dehydrogenase, and ferritin; as well as low levels of ADAMTS-13 activity and antibody. Serology tests depicted positive IgM and IgG antiphospholipid antibodies (anti-cardiolipin and anti-β2-glycoprotein I antibodies). No side effects of therapeutic plasma exchange were recorded. After the completion of therapeutic plasma exchange, patients improved clinically and gradually recovered neurologically (after 27–32 days). To conclude, in life-threatening COVID-19, especially when immune dysregulation features such as antiphospholipid antibodies exist, therapeutic plasma exchange could be an effective rescue therapy.
format Online
Article
Text
id pubmed-7550946
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75509462020-10-23 Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series Alharthy, Abdulrahman Faqihi, Fahad Balhamar, Abdullah Memish, Ziad A Karakitsos, Dimitrios SAGE Open Med Case Rep Case Report We present a case series of three patients with COVID-19 who were admitted to our intensive care unit due to acute respiratory distress syndrome, brain infarction, pulmonary embolism, and antiphospholipid antibodies. We applied therapeutic plasma exchange on all cases. On intensive care unit admission, all patients had low (<10) Glasgow Coma Scale, and central nervous imaging showed multiple brain infarctions. COVID-19 was confirmed by reverse transcriptase polymerase chain reaction assays. Patients underwent rescue therapeutic plasma exchange using the Spectra Optia(TM) Apheresis System (Terumo BCT Inc., USA), which operates with acid-citrate dextrose anticoagulant as per Kidney Disease Improving Global Outcomes 2019 guidelines. A dose of 1.5 plasma volume was used for the first dose and then 1 plasma volume daily for a total of five doses. Plasma was replaced with Octaplas LG(®) (Octapharma AG, USA), which is an artificial fresh frozen plasma product that has undergone viral inactivation by prion reduction technology. We administered ARDS-net/prone positioning ventilation, empiric antiviral treatment, therapeutic anticoagulation, and intensive care unit supportive care. Laboratory tests showed lymphocytopenia; elevated levels of D-dimer, fibrinogen, total bilirubin, C-reactive protein, lactate dehydrogenase, and ferritin; as well as low levels of ADAMTS-13 activity and antibody. Serology tests depicted positive IgM and IgG antiphospholipid antibodies (anti-cardiolipin and anti-β2-glycoprotein I antibodies). No side effects of therapeutic plasma exchange were recorded. After the completion of therapeutic plasma exchange, patients improved clinically and gradually recovered neurologically (after 27–32 days). To conclude, in life-threatening COVID-19, especially when immune dysregulation features such as antiphospholipid antibodies exist, therapeutic plasma exchange could be an effective rescue therapy. SAGE Publications 2020-10-08 /pmc/articles/PMC7550946/ /pubmed/33101686 http://dx.doi.org/10.1177/2050313X20964089 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Alharthy, Abdulrahman
Faqihi, Fahad
Balhamar, Abdullah
Memish, Ziad A
Karakitsos, Dimitrios
Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
title Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
title_full Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
title_fullStr Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
title_full_unstemmed Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
title_short Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
title_sort life-threatening covid-19 presenting as stroke with antiphospholipid antibodies and low adamts-13 activity, and the role of therapeutic plasma exchange: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550946/
https://www.ncbi.nlm.nih.gov/pubmed/33101686
http://dx.doi.org/10.1177/2050313X20964089
work_keys_str_mv AT alharthyabdulrahman lifethreateningcovid19presentingasstrokewithantiphospholipidantibodiesandlowadamts13activityandtheroleoftherapeuticplasmaexchangeacaseseries
AT faqihifahad lifethreateningcovid19presentingasstrokewithantiphospholipidantibodiesandlowadamts13activityandtheroleoftherapeuticplasmaexchangeacaseseries
AT balhamarabdullah lifethreateningcovid19presentingasstrokewithantiphospholipidantibodiesandlowadamts13activityandtheroleoftherapeuticplasmaexchangeacaseseries
AT memishziada lifethreateningcovid19presentingasstrokewithantiphospholipidantibodiesandlowadamts13activityandtheroleoftherapeuticplasmaexchangeacaseseries
AT karakitsosdimitrios lifethreateningcovid19presentingasstrokewithantiphospholipidantibodiesandlowadamts13activityandtheroleoftherapeuticplasmaexchangeacaseseries